miR-21 expression predicts prognosis in diffuse large B-cell lymphoma

Int J Clin Exp Pathol. 2015 Nov 1;8(11):15019-24. eCollection 2015.


Background: Expression patterns of microRNAs in serum are involved in potentially biomarkers for various diseases. The aim of the study was to investigate the expression level of miR-21 in diffuse large B cell lymphoma (DLBCL) and its prognostic value.

Methods: Real-time quantitative polymerase chain reaction (qRT-PCR) was used to measure miR-21 levels in serum samples from 112 patients with DLBCL as well as in serum samples from 45 healthy controls. The associations between miR-21 expression and clinicopathologic parameters and overall survival of the patients, were analyzed by chi-square test and Kaplan-Meier method. The Cox proportional hazards regression analyses were performed to estimate the prognostic values for patient survival prediction.

Results: We found that serum miR-21 expression was markedly upregulated in patients with DLBCL than healthy controls. Increased miR-21 expression was significantly correlated with B symptoms, IPI score, CHOP-like treatment and Rituximab (all Ps<0.05). Moreover, DLBCL patients with miR-21 higher expression have shown significantly worse overall survival than those with lower miR-21 expression. And miR-21 expression was an independent prognostic marker of overall survival in a multivariate analysis (P=0.001, HR: 4.404, 95% CI: 1.770-10.956).

Conclusion: The results of the present study suggested miR-21 expression level could be a novel potential biomarker for DLBCL prognosis.

Keywords: MicroRNA-21; diffuse large B-cell lymphoma; prognosis.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics*
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Male
  • MicroRNAs / blood
  • MicroRNAs / genetics*
  • Middle Aged
  • Prednisone / therapeutic use
  • Prognosis
  • Proportional Hazards Models
  • Real-Time Polymerase Chain Reaction
  • Vincristine / therapeutic use


  • Biomarkers, Tumor
  • MIRN21 microRNA, human
  • MicroRNAs
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol